A Phase I/II Trial of A Combination of Paclitaxel and Trastuzumab with Daily Irradiation OR Paclitaxel Alone with Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates with Muscle-Invasive Bladder Cancer
This phase I/II trial is studying the side effects of giving paclitaxel together with
radiation therapy with or without trastuzumab and to see how well it works to kill any
remaining tumor cells in patients who have undergone surgery for bladder cancer. Drugs used
in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor
cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses
high-energy x-rays to kill tumor cells. Paclitaxel may also make tumor cells more sensitive
to radiation therapy. Monoclonal antibodies, such as trastuzumab, can block tumor growth in
different ways. Some block the ability of tumor cells to grow and spread. Others find tumor
cells and help kill them or carry tumor-killing substances to them. Giving paclitaxel
together with radiation therapy and trastuzumab may kill more tumor cells. Giving these
treatments after surgery may kill any remaining tumor cells.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.